NO

Novo Nordisk A/S

NOV ·

Novo Nordisk A/S (NOV) is a Biotechnology company in the Healthcare sector, listed on Deutsche Borse Xetra. This page provides the complete earnings calendar, dividend schedule, and financial data for Novo Nordisk A/S in 2026. The next earnings report is expected on November 4, 2026.

Earnings calendar

Next earnings date

04 Nov 2026

In 76 days

EPS estimate

0.75

Revenue estimate

11.1B

Past earnings

05 Aug 2026
EPS actual
0.78 (-2.1%)
estimate 0.79
Revenue actual
11.0B (+0.3%)
estimate 11.0B
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
06 May 2026
EPS actual
1.02 (+10.5%)
estimate 0.92
Revenue actual
10.8B (+0.6%)
estimate 10.7B
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
04 Feb 2026
EPS actual
0.95 (+2.8%)
estimate 0.92
Revenue actual
12.4B (+2.9%)
estimate 12.1B
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
Beat Miss usd

Latest earnings analysis

Novo Nordisk A/S missed consensus on EPS but exceeded expectations on revenue in its latest earnings report, with EPS of USD 0.776 falling 2.1% short of estimates and revenue of USD 11.02 billion exceeding estimates by 0.3%. Both EPS and revenue also came in ahead of expectations in the previous report.

Dividend calendar

Next ex-dividend

—

Not scheduled

Next payment

—

Not scheduled

Dividend amount

—

Not available

Past dividends

Ex-dividend Payment Amount
27 Mar 2026 31 Mar 2026 1.22

EPS (Earnings Per Share)

Revenue

Dividend per share

Company profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Sector
Healthcare
Industry
Biotechnology
Country
Denmark
Exchange
Deutsche Borse Xetra
CEO
Maziar Mike Doustdar
Employees
77,406
IPO date
07 Jun 2001
ISIN
US6701002056
Website
novonordisk.com

Frequently asked questions

When does Novo Nordisk A/S (NOV) next report earnings?

Novo Nordisk A/S (NOV) is scheduled to report earnings on November 4, 2026.

What was Novo Nordisk A/S's most recent earnings date?

Novo Nordisk A/S (NOV) last reported earnings on August 5, 2026.

Where is Novo Nordisk A/S stock listed?

Novo Nordisk A/S (NOV) is listed on Deutsche Borse Xetra.